Research Article

Risk of metabolic syndrome in the first degree relatives of women with polycystic ovarian syndrome

Yashwant A. M.¹, Prashant R. Kokiwar²*, Gazala Taiseen³

¹Assistant Professor, Department of Community Medicine, Malla Reddy Institute of Medical Sciences, Suraram, Telangana, India
²Professor & HOD, Department of Community Medicine, Malla Reddy Institute of Medical Sciences, Suraram, Telangana, India
³MBBS final year student, Malla Reddy Institute of Medical Sciences, Suraram, Telangana, India

Received: 18 September 2015
Accepted: 29 September 2015

*Correspondence:
Dr. Prashant R. Kokiwar,
E-mail: kokiwar@gmail.com

ABSTRACT

Background: Poly cystic ovarian syndrome (PCOS) is a common disorder, affecting approximately 4 – 8% of women in the reproductive age group. First degree relatives (FDRs) of women with PCOS are at high risk developing endocrine and metabolic co-morbidities of PCOS such as obesity, insulin resistance (IR), and impaired insulin sensitivity, hyperlipidemia and metabolic syndrome (MBS). Present study was conducted with the objectives to evaluate the risk of metabolic syndrome in FDRs of women with PCOS and to compare the risk of metabolic syndrome in FDRs of women with PCOS with age, sex and relation matched FDRs of women with no PCOS. To give suitable recommendations based on the findings of the study.

Methods: Hospital based cross sectional analytical study was carried out. 50 FDRs of women with PCOS were compared against same number of age, sex and relation matched FDRs of women with no PCOS.

Results: The prevalence of MBS was significantly higher i.e. 34% among FDRsPCOS compared to FDRsControls (8%) (p < 0.05). The FDRsPCOS were 5.92 times more at risk of MBS than FDRsControls (p < 0.05). Relation wise it was found that the fatherPCOS and motherPCOS were 1.5 times at risk, brotherPCOS were 14.26 and sisterPCOS were 12.43 times at risk of MBS than their counterparts.

Conclusions: Thus it is concluded that the FDRsPCOS are at high risk of MBS than FDRsControls.

Keywords: Metabolic syndrome, Polycystic ovarian syndrome, Disorder, Obesity

INTRODUCTION

Poly cystic ovarian syndrome (PCOS) is a common disorder, affecting approximately 4 – 8% of women in the reproductive age group.¹

The classic form of this syndrome includes amenorrhoea, anovulation, infertility, hirsutism, obesity and enlarged bilateral ovaries with cysts. There is an increased risk of diabetes mellitus (DM) and cardiovascular (CVS) diseases. In addition, insulin resistance (IR) and hyperinsulinaemia commonly occur. Lipoprotein abnormalities are also common in PCOS. Other PCOS complications include sleep apnoea and infertility. The high familial incidence of PCOS suggests its genetic origin.²

In view of high prevalence of affected individuals within families of PCOS women, a genetic basis for this syndrome has been suggested. This has been evaluated in different population through phenotypic and family aggregation studies.³
First degree relatives (FDRs) of women with PCOS are at high risk developing endocrine ad metabolic co-morbidities of PCOS such as obesity, IR, and impaired insulin sensitivity, hyperlipidaemia and metabolic syndrome. Abnormalities in insulin action and secretion, glucose tolerance, and lipid levels demonstrate familial aggregation in FDRs of women with PCOS. Elevated LDL cholesterol levels are the most consistent lipid abnormality in affected women as well as their sisters and mothers. In addition the prevalence of metabolic syndrome is increased in these groups.

Keeping in view this increased risk of metabolic syndrome in FDRs of women with PCOS, we decided to study the risk of metabolic syndrome in FDRs of women with PCOS.

Early detection of metabolic syndrome in FDRs of women with PCOS is important as metabolic syndrome may predict a higher risk for CVS component. Hence early detection of metabolic syndrome can prevent the risk of CVS diseases in FDRs of women with PCOS. An opportunity for preventive health care exists and may alleviate risks for metabolic and CVS abnormalities in FDRs of women with PCOS.

With this idea, the present study was planned to compare the risk of metabolic syndrome in FDRs of women with PCOS with age, sex and relation matched controls in FDRs of women with no PCOS. This probably will help to establish that FDRs of women with PCOS are at high risk of developing metabolic syndrome.

Another reason that led us to consider to plan this study is that in our literature search of more than 50 studies on PCOS, there are very few studies from Asia and very rare of Indian origin.

Hence present study was undertaken with the main objective to study the risk of metabolic syndrome in FDRs of women with PCOS.

**METHODS**

**Study type and design**

Hospital based cross sectional analytical study.

**Study population**

FDRs of women with PCOS & FDRs of women with no PCOS

**Place of study**

Malla reddy hospital which is attached to Malla Reddy Institute of Medical Sciences, Hyderabad, Telangana, India.

**Duration of study**

The study was conducted from January 2014 to October 2014.

**Sample size**

50 FDRs of women with PCOS were compared against same number of age, sex and relation matched FDRs of women with no PCOS.

**Selection criteria**

A. For women with PCOS

**Inclusion criteria**

Known cases of PCOS as diagnosed by Gynecologist

**Exclusion criteria**

1. Not willing to participate in the study.

B. For FDRs of women with PCOS.

**Inclusion criteria**

1. First degree relatives only
2. Not on treatment for DM, Hyperlipidemia and HT

**Exclusion criteria**

1. Not willing to participate
2. Seriously ill

C. For women with no PCOS

**Inclusion criteria**

1. No history of PCOS
2. Not on treatment for DM, Hyperlipidemia and HT

**Exclusion criteria**

1. Not willing to participate
2. History of PCOS in their families
3. Seriously ill

D. For FDRs of women with no PCOS.

**Inclusion criteria**

1. First degree relatives only
2. Not on treatment for DM, Hyperlipidemia and HT

**Exclusion criteria**

1. Not willing to participate
2. Seriously ill
Ethical considerations

Institutional ethics committee permission was obtained. Informed consent was obtained from the women with PCOS and no PCOS as well as their FDRs if they are more than 18 years of age. If they are less than 18 years of age, then their mother’s or father’s consent was obtained. The study participants found at risk of metabolic syndrome, were given counseling and health education. Those with abnormal investigation reports were referred to the appropriate department for further management.

Methodology

Women with PCOS as diagnosed by Gynecologists were contacted. Necessary permission from the department was obtained. The nature of study was explained to women with PCOS. Confidentiality was ensured. They were asked to come with their FDRs on a fixed day early morning with 8-10 hours of fasting. The FDRs were included only if they satisfied the selection criteria.

The socio-demographic information, anthropometry and blood pressure were recorded in a pre-designed questionnaire. Then their blood samples were collected by the laboratory technician to be analyzed for lipid profile and fasting glucose. The blood samples were sent to the hospital laboratory and reports were collected.

The study subjects were contacted and asked to collect their reports. At this point of time, they were informed about the risk of metabolic syndrome and CVS diseases based on the reports. Health education was given with respect to adoption of healthy life styles and its importance; nutrition education and its importance. Those with abnormal reports were referred to endocrinologist.

The control group included age, sex and relation matched FDRs of women with no PCOS. A confirmation that these women do not have PCOS was obtained from the Gynecologist. Same procedure as mentioned above for experimental group was followed for this group also.

Metabolic syndrome was defined as follows:

The expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III [ATP III]) recently published a consensus definition on insulin resistance syndrome (also termed as metabolic syndrome) based on abnormality in three or more of five component traits as follows.6

1. Abdominal obesity (waist circumference)
   a. Men > 102 cm
   b. Women > 88 cm
2. Blood pressure > 130/ > 85 mmHg
3. Triglycerides > 150 mg/dl
4. HDL Cholesterol
   a. Men < 40 mg/dl
   b. Women < 50 mg/dl
5. Fasting glucose > 110 mg/dl

Height was measured with the help of a height rod. The person was asked to remove shoes or chappals. The height was measured to the nearest of 0.5 cm. For recording weight, the weight machine was standardized. It was ensured that it is kept on a flat and firm surface with its arrow on zero mark every time. The person was asked to stand with minimum clothing and without shoes or chappals. The weight was recorded to the nearest of 0.5 kg. Based on height and weight, body mass index (BMI) was calculated as weight in kg divided by height in square meter.

Measurement of waist circumference was done with the help of a measuring tape as per the World Health Organizations (WHO) guidelines.7 Subjects were considered to have abdominal obesity if waist circumference was more than or equal to 102 cm in males and more than or equal to 88 cm in females.6

After a rest for a while, blood pressure (BP) was measured with the help of a sphygmomanometer in sitting position, putting the sphygmomanometer at the level of the heart. The procedure for recording BP was followed as per the WHO guidelines.8 As per this, three readings were obtained at an interval of five minutes and the lowest reading was recorded. For classifying the BP measurement, classification given by WHO was adopted.8

Investigations like fasting glucose and lipid profile {total cholesterol (TC), triglycerides (TG), and low density lipoproteins (LDL), high density lipoproteins (HDL)} was done.

Sample collection and methods of estimation

The blood samples (5ml) were collected by venipuncture of cubital vein. For accurate comparison, fasting morning serum samples were obtained. The blood samples were collected in a plain redtop venipuncture tube without additives or anti-coagulants for preparation of serum. The blood was allowed to clot for serum samples. The specimens were centrifuged to separate the serum from the cells and analyzed for Triglycerides (TG), Total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) by the following methods:

Estimation of fasting glucose

Fasting glucose was determined by GOD-POD method.

Estimation of serum HDL-C

Serum HDL-C was estimated by direct method using Jeev diagnostic kit. The system utilizes a combination of surfactants, phosphoric acid, organic acids, and inorganic acids, specifically binding LDL-C, VLDL-C and
Only HDL cholesterol was detected by the enzymatic CHOD/ POD method.

**Estimation of Serum Triglycerides**

Serum triglyceride was estimated by Glycerol phosphate oxidase/ Peroxidase (GPO/POD) colorimetric endpoint method using Jeev diagnostic kit. Triglyceride was hydrolyzed by lipoprotein lipase to free fatty acids and glycerol. Glycerol kinase converts glycerol to glycerol phosphate, which gets oxidized to dihydroxy acetone phosphate and hydrogen peroxide by glycerol phosphate oxidase. Hydrogen peroxide so formed reacts with 4-amino antipyrine in the presence of peroxidase to give a purple colored complex which is read at 505 nm.

**Calculation of LDL-C**

LDL-C is obtained using Friedwald’s formula as given below:

\[
LDL-C = \text{Total cholesterol} - (\text{HDL-C} + \text{VLDL-C})
\]

**Table 1: Prevalence of metabolic syndrome among cases and controls.**

| FDRPCOS | Controls |
|---------|----------|
| **Metabolic Syndrome** | **Male** | **Female** | **Total** | **Male** | **Female** | **Total** |
| Yes     | 08 (32)  | 09 (36)  | 17 (34)  | 02 (08)  | 02 (08)  | 04 (08)  |
| No      | 17 (68)  | 16 (64)  | 33 (66)  | 23 (92)  | 23 (92)  | 46 (92)  |
| Total   | 25 (100) | 25 (100) | 50 (100) | 25 (100) | 25 (100) | 50 (100) |

* Figures in the parentheses indicate percentages

Maximum study subjects were in the age group of 15-24 years (48% FDRPCOS and 46% controls). Minimum were in the age group of 45 – 54 years. Very few study subjects were illiterate i.e. a total of 9%. (14% of FDRPCOS and 4% controls). 38% of study subjects were educated more than Intermediate. Only 2% of study subjects were unemployed, 22% were home maker and 33% were students. No one was found belonging to class V. Only 4% belonged to class IV. Distribution of study subjects in social classes I to III is almost similar ranging from 30 – 35%. This is because; they were matched for relation with index case. Maximum FDRs are brothers (35%) followed by sisters (28%) and mothers (26%). Fathers are only 11%. Prevalence of metabolic syndrome (MBS) is shown in table 1. The prevalence of MBS among FDRPCOS is 34% compared to only 8% among controls. Among male FDRPCOS it is 32% compared to 8% controls and among female FDRPCOS, it is 36% compared to 8% controls. Table 2 shows the risk of MBS in FDRPCOS which is the main objective of the present study. As also mentioned in table 1, the prevalence of MBS among FDRPCOS is 34% compared to only 8% among controls. This difference is found to be statistically significant. (Chi square = 10.2, p = 0.001). It is observed that, the FDRPCOS are 5.92 times more likely to develop MBS than their counterparts. And this risk is also found statistically significant. (Z = 2.962, p = 0.0031).

**Table 2: Risk of metabolic syndrome in first degree relatives of women with PCOS.**

|          | Metabolic Syndrome Present | Metabolic Syndrome Absent | Total |
|----------|----------------------------|---------------------------|-------|
| FDRPCOS  | 17 (34)                    | 33 (66)                   | 50 (50) |
| Controls | 04 (08)                    | 46 (92)                   | 50 (50) |
| Total    | 21 (21)                    | 79 (79)                   | 100 (100) |

* Figures in the parentheses indicate percentages

X2 = 10.2; df = 1; p = 0.001; Odds Ratio = 5.9242; 95% C.I. = 1.8251 – 19.2259; Z = 2.962; p = 0.0031.

Table 3 shows clinical and biochemical characteristics in brothersPCOS and brotherControls. Mean age, anthropometric and blood pressure characteristics are almost similar in both the groups (p >0.05). Among biochemical mean
values, FBG, HDL, LDL, and TC are significantly more among fathers_{PCOS} than father_{Controls}.

Table 4 shows clinical and biochemical characteristics in mothers_{PCOS} and mother_{Controls}. Among all the characteristics studied, only BMI is found to be significantly higher among mothers_{PCOS} than mother_{Controls} (p < 0.05). For all other characteristics, the difference of mean is not found to be significant (p > 0.05).

### Table 3: Clinical and biochemical characteristics in Brother_{PCOS} and Brother_{Controls}.

|                  | Brother_{PCOS} (18) | Brother_{Controls} (17) | T      | p    |
|------------------|--------------------|-------------------------|--------|------|
| Age              | 21.44±4.24         | 21.41±4.37              | 0.0344 | 0.9728|
| BMI              | 22.42±4.10         | 21.02±2.99              | 1.1484 | 0.2591|
| WC               | 85.6±12.83         | 78.88±9.93              | 1.5714 | 0.1256|
| SBP              | 116.44±11.55       | 117.64±6.35             | 1.4729 | 0.1503|
| DBP              | 80±7.66            | 75.29±7.17              | 1.8753 | 0.0696|
| FBG              | 97.38±4.14         | 86.47±9.10              | 2.6516 | 0.012 |
| Triglycerides    | 129.61±37.3        | 129.76±54.99            | 0.0095 | 0.9925|
| HDL              | 37.11±4.6          | 29±7.936                | 3.7273 | 0.0007|
| LDL              | 119.27±41.11       | 87.47±43.88             | 2.2137 | 0.0339|
| VLDL             | 24.72±80.48        | 25.58±11.09             | 0.2586 | 0.7975|
| TC               | 228±44.38          | 151.23±40.89            | 5.3151 | 0.0001|

BMI=body mass index, WC=waist circumference, DBP=diastolic blood pressure, SBP=systolic blood pressure, FBG=fasting blood glucose, HDL=high density lipoproteins, LDL=low density lipoproteins, VLDL=very low density lipoproteins, TC=total cholesterol

### Table 4: Clinical and biochemical characteristics in Mother_{PCOS} and Mother_{Controls}.

|                  | Mother_{PCOS} (12) | Mother_{Controls} (14) | T      | p    |
|------------------|--------------------|------------------------|--------|------|
| Age              | 39.16±5.78         | 39.71±6.79             | 0.2203 | 0.8275|
| BMI              | 25.53±5.41         | 22.17±4.26             | 2.0905 | 0.0473|
| WC               | 82.25±17.92        | 86.64±10.9             | 0.7670 | 0.4505|
| SBP              | 110.83±9           | 115±6.5                | 1.3683 | 0.1835|
| DBP              | 74.16±9            | 73.57±8.41             | 0.1727 | 0.8644|
| FBG              | 103.83±26.46       | 108.7±68.77            | 0.2007 | 0.8426|
| Triglycerides    | 115.5±64.17        | 164±1489.87            | 1.5624 | 0.1313|
| HDL              | 38±5.84            | 36.92±4.66             | 0.5245 | 0.6047|
| LDL              | 120.41±44.21       | 134.85±38.48           | 0.8909 | 0.3819|
| VLDL             | 26.58±16.98        | 32.85±17.78            | 0.9150 | 0.3692|
| TC               | 182.08±46.04       | 204.28±37.16           | 1.3609 | 0.1862|

BMI=body mass index, WC=waist circumference, DBP=diastolic blood pressure, SBP=systolic blood pressure, FBG=fasting blood glucose, HDL=high density lipoproteins, LDL=low density lipoproteins, VLDL=very low density lipoproteins, TC=total cholesterol

Table 5 shows clinical and biochemical characteristics in fathers_{PCOS} and father_{Controls}. The difference of mean values between fathers_{PCOS} and father_{Controls} in all studied parameters is statistically not significant (p > 0.05) except mean HDL (P < 0.05).

Table 6 shows clinical and biochemical characteristics in sister_{PCOS} and sister_{Controls}. Only mean value of FBG is significantly higher in sister_{PCOS} than sister_{Controls} (p < 0.05). Difference in mean of all other characteristics is statistically not significant (p > 0.05).

### DISCUSSION

The present study was conducted with the objective to study the risk of metabolic syndrome (MBS) in FDRs of
women with PCOS. They were compared with age, sex and relation matched FDRs of women with no PCOS.

For all descriptive purposes, the first degree relatives of women with PCOS will be termed as \( \text{FDR}_{PCOS} \) (Fathers\(_{PCOS}\), Mothers\(_{PCOS}\), Brothers\(_{PCOS}\) and Sisters\(_{PCOS}\)) and first degree relatives of women with no PCOS will be termed as controls (Fathers\(_{Controls}\), Mothers\(_{Controls}\), Brothers\(_{Controls}\) and Sisters\(_{Controls}\)).

We found that the prevalence of MBS was very high among \( \text{FDR}_{PCOS} \) i.e. 34% whereas among controls, it was only 8%. This difference was statistically significant (\( X^2 = 10.2, p = 0.001 \)). Similarly, the risk of MBS was 5.9 times more for \( \text{FDR}_{PCOS} \) than controls. This risk is also found statistically significant (\( Z = 2.962, p = 0.0031 \)).

### Table 5: Clinical and biochemical characteristics in \( \text{father}_{PCOS} \) and \( \text{father}_{Controls} \).

|           | \( \text{father}_{PCOS} \) (6) | \( \text{father}_{Controls} \) (5) | t     | p   |
|-----------|-------------------------------|-----------------------------------|-------|-----|
| Age       | 46.3±6.59                     | 45.6±7.09                        | 0.1769| 0.8635 |
| BMI       | 23.2±2.85                     | 23.35±4.49                      | 0.0675| 0.9477 |
| WC        | 81.6±21.07                    | 87±15.93                        | 0.4656| 0.6526 |
| SBP       | 123.3±5.16                    | 120±7.07                        | 0.9040| 0.3896 |
| DBP       | 83.3±10.32                    | 80±5                            | 0.7149| 0.4928 |
| FBG       | 104.16±9.43                   | 93.4±13.14                     | 1.5822| 0.1481 |
| Triglycerides | 118.16±34.85                | 157±43.25                      | 1.6711| 0.1290 |
| HDL       | 40±5.93                       | 33±4.64                       | 2.4299| 0.0380 |
| LDL       | 126±41.08                     | 122±43.15                      | 0.1572| 0.8785 |
| VLDL      | 25±10.27                      | 31±8.86                       | 1.0248| 0.3322 |
| TC        | 184.6±44.86                   | 186±39.22                      | 0.0356| 0.9548 |

BMI=body mass index, WC=waist circumference, DBP=diastolic blood pressure, SBP=systolic blood pressure, FBG=fasting blood glucose, HDL=high density lipoproteins, LDL=low density lipoproteins, VLDL=very low density lipoproteins, TC=total cholesterol

### Table 6: Clinical and biochemical characteristics in \( \text{sister}_{PCOS} \) and \( \text{sister}_{Controls} \).

|            | \( \text{sister}_{PCOS} \) (14) | \( \text{sister}_{Controls} \) (14) | T    | P   |
|------------|---------------------------------|------------------------------------|------|-----|
| Age        | 22.6±6.40                       | 21.8±4.31                          | 0.3831| 0.7048 |
| BMI        | 19.3±3.7                        | 18.1±2.92                          | 0.9367| 0.3575 |
| WC         | 75.4±13.91                      | 78±11.3                           | 0.5387| 0.5947 |
| SBP        | 110.7±11.41                     | 105±5.18                          | 1.7050| 0.1001 |
| DBP        | 76.4±12.15                      | 68.5±9.49                         | 1.9052| 0.0679 |
| FBG        | 94.2±12.87                      | 85.5±6.42                         | 2.2477| 0.0333 |
| Triglycerides | 118.14±38.64                 | 139.21±62.17                      | 1.0770| 0.291 |
| HDL        | 36.14±5.85                      | 32.2±4.44                         | 2.0022| 0.0558 |
| LDL        | 112.92±27.96                    | 97.4±25.65                        | 1.5285| 0.1385 |
| VLDL       | 23.5±7.6                        | 27.5±12.42                        | 1.0243| 0.3153 |
| TC         | 172.6±29.58                     | 157.1±24.37                       | 1.5132| 0.1423 |

Shabir I et al also reported from Kashmir that the prevalence of MBS was 22% among \( \text{FDR}_{PCOS} \). Akbarzadeh et al also observed a high prevalence of MBS as 29.35% in \( \text{father}_{PCOS} \) compared to only 8.8% of fathers of women in the control group.\(^{1,11}\) These findings suggest that the high prevalence of MBS in \( \text{FDR}_{PCOS} \) is due to familial aggregation.

We observed that, the prevalence of MBS was 50% in \( \text{father}_{PCOS} \) and 40% in \( \text{father}_{Controls} \).
Shabir et al. revealed very high prevalence i.e. 56%. Coviello et al. observed that the prevalence of MBS was 42% in fatherPCOS and 32% in fatherControls. Akbarzadeh et al. observed that the prevalence of MBS was 29.35% in fatherPCOS as against 8.8% in fatherControls. Gabrielli L et al. reported prevalence of diabetes (DM) and impaired glucose tolerance (IGT) as 27% and 31% among motherPCOS.2, 13

Prevalence of MBS is 41.6% in motherPCOS compared to 14.28% in motherControls in the present study.

Shabir et al. reported almost double i.e. 80% prevalence of MBS in motherPCOS. Gabrielli L et al. observed that the prevalence of DM & IGT was 16% and 30% respectively in motherPCOS, and that of impaired fasting glucose (IFG) was 3% in motherPCOS.

In the present study, among brotherPCOS the prevalence of MBS was 27.7% compared to nil among brotherControls.

But Shabir et al. did not find any brotherPCOS with MBS. Whereas Coviello et al. observed this rate as 22% in brotherPCOS compared to only 9% among brotherControls. Gabrielli L et al. found no DM in brotherPCOS but IFG was present in 4% of brotherPCOS.11, 13

We observed that the prevalence of MBS in sisterPCOS was 28.57% and no case of MBS in sisterControls.

Shabir et al. also reported that 25% of sisterPCOS were having MBS. Bulent O et al. found no DM in sisterPCOS but reported that prevalence of IGT was 5%.11, 13

In the present study, we compared the mean values of clinical and biochemical parameters among FDRPCOS and FDRControls.

For brothers, we found that FBG, HDL, LDL & TC mean values were significantly higher in brotherPCOS than brotherControls. But the difference in mean values of other parameters was not significant statistically (p > 0.05).14 Susan Sam et al. found that SBP was similar among brotherPCOS and brotherControls, but the difference in DBP was significant. Akbarzadeh et al. found no statistically significant difference for blood pressure which is similar to our findings.14 Susan Sam et al. reported no significant difference of mean BMI and WC and we also observed the same.2 But Shabir I et al. reported a prevalence of 73.6% of BMI > 23 kg/m² in brotherPCOS.11 Likewise, Coviello AD et al. also found higher BMI in brotherPCOS.2 For brotherPCOS, we found that mean value of TC, LDL, HDL & FBG is significantly higher. Susan Sam et al. also reported that the mean value of TC, LDL higher, similar to our study but TG was also higher in brotherPCOS which is not significantly higher in the present study.3 For HDL, they found no significant difference. Shabir I et al. observed that TG > 150 mg/dl was present in 42% of brotherPCOS.11 Similar to our study findings, Murat Y et al. also reported that difference in mean of age, BMI, WHR, SBP, DBP was not significant and that of TC, LDL was significant for brothers.15

Mean difference in clinical and biochemical characteristics for mothers in the present study revealed that except higher significant BMI value in motherPCOS, all other characteristics were similar for motherPCOS and motherControls. Akbarzadeh found that the average blood pressure was high among motherPCOS.14 SBP > 130 mmHg and DBP > 85 mmHg was present in 47% each of motherPCOS in a study by Shabir I et al.11 They also found that the prevalence of BMI > 23 kg/m², fasting glucose > 100 mg/dl, and TG > 150 mg/dl was 95.4%, 12% and 76% respectively. Murat Y et al. revealed that age, BMI, HDL mean value were not significantly different but mean WHR, SBP, DBP, TC, LDL, TG were significantly higher in motherPCOS.15 He also found that prevalence of glucose intolerance was 40% among motherPCOS.

For fathers, all characteristics were almost similar (p > 0.05) except HDL, which was significantly higher among fatherPCOS.

Whereas Murat Y et al. reported that except age and BMI, all other characteristics were significantly higher in fatherPCOS.15 Akbarzadeh M et al. revealed that average blood pressure was significantly more in fatherPCOS.14 Shabir I et al. reported that the prevalence of SBP > 130 mmHg, DBP > 85 mmHg, BMI > 23 kg/m², IFG > 100 mg/dl, TG > 150 mg/dl, was 45%, 45%. 82.6%, 20%, and 65% respectively among fatherPCOS.11 Akbarzadeh et al. also reported that 14.7% of fatherPCOS were hypertensive and 29.4% were diabetics and 17.6% had high total cholesterol levels.2 Coviello AD et al.12 found higher BMI in fatherPCOS. Murat Y et al. observed that 52% of fatherPCOS were having glucose intolerance.15

In the present study, among sisters, only mean FBG was significantly higher among sisterPCOS than sisterControls. All other characteristics mean was not significantly different. Murat Y et al. also found that age, BMI, WHR, SBP, DBP, TC, LDL, HDL, TG were similar for sisterPCOS and sisterContacts and this finding is similar to our study.15 But Akbarzadeh et al. found that average blood pressure was higher in sisterPCOS.11 Shabir I et al. reported the prevalence of SBP > 130 mmHg, DBP > 85 mmHg, BMI > 23 kg/m², IFG > 100 mg/dl, TG > 150 mg/dl, as 15%, 15%, 77.2%, 12%, and 45% respectively for sisterPCOS.14

Thus from the present study, it is clear that the FDRPCOS are at high risk of having MBS than their counterparts. Some findings in the present study are not found to be significant, especially when the comparison was made between individual relationships. This may be due to a very small sample of fathers etc. But jointly, when compared with controls, FDRPCOS are significantly at high risk of MBS.
CONCLUSION

It was found that the prevalence of metabolic syndrome among FDRs-PCOS is significantly very high i.e. 34% vs 8% in FDRs Controls. The risk of MBS is significantly high for brothersPCOS and sistersPCOS but not for fathersPCOS and mothersPCOS. This study warrants further research into prevalence of MBS and other androgenic abnormalities among FDRs of PCOS. This will help establish that screening should be carried out for FDRs of women who are diagnosed as having PCOS in any hospital.

ACKNOWLEDGEMENTS

We are thankful to Indian Council of Medical Research (ICMR) who has provided us opportunity to carry out this study through ICMR STS Programme.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J ClinEndocrinolMetab. 2009;88(5):2031-6.
2. Akbarzadeh M, Moradi F, Dabbaghmanesh MH, Jafari P, Parsanezhad ME. A survey of metabolic syndrome in first degree relatives (fathers) of patients with polycystic ovarian syndrome. J EndocrinolMetab and Diabetes of South Africa. 2013;18(2):98-103.
3. Recabarren SE, Smith R, Rios R, Maliqueo M, Echihuru B, Codner E et al. Metabolic profile in sons of women with polycystic ovary syndrome (PCOS). J ClinEndocrinolMetab. 2008;93(5):1820-6.
4. Raissouni N, Kolesnikov A, Purushothaman R, Sinha S, Bhandari S, Bhangool A et al. Altered glucose disposition and insulin sensitivity in peripubertal first degree relatives of women with polycystic ovary syndrome. Int J PediatrEndocrinol. 2012;2012(1):14.
5. Sam S, Coviello AD, Sung Ya, Legro RS, Dunaif A. Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care. 2008;31(6):1237-41.
6. Pankow JS, Jacobs DR, Steinberger J. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care. 2004;27:775-80.
7. World Health Organization: Physical status: The use and interpretation of anthropometry: WHO Tech Rep Series. 1995;854:424-38.
8. Park K. Park’s Textbook of Preventive and Social Medicine. 21st edition, M/s BanarasidasBhanot Publishers, Jabalpur, 2005.
9. Kimberly MM, Leary ET, Cole TG, Waymack PP, Selection, Validation, Standardization, and Performance of a Designated Comparison Method for HDL-Cholesterol for Use in the Cholesterol Reference Method Laboratory Network. Clinical Chemistry. 1999;45:1803-12.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
11. Shabir I, Ganie MA, Zargar MA, Bhat D, Mir MM, Jan A, et al. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J EndocrinolMetab. 2014;18(3):364–9.
12. Coviello AD, Sam S, Legro RS, Dunaif A. High prevalence of Metabolic syndrome in first-degree male relatives of women with Polycystic ovary syndrome is related to high rates of obesity. J Clin Endocrinol Metab. 2009;94:4361-6.
13. Gabrielli L, AquinoEstela ML. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reproductive Biology and Endocrinology2012;10:96. Available at: http://www.rbjecom/content/10/1/96.
14. Akbarzadeh M, Moradi F, Dabbaghmanesh MH, Jafari P, Parsanezhad ME. Abnormal blood pressure and hyperandrogenemia in first degree relatives of women with polycystic ovarian syndrome referring to gynecology clinics of Shiraz Medical University. International Journal of Obstetrics and Gynecology. 2014;2(2):40-4.
15. Murat Y, Bukan M, ErsoyR, Karakoc A, Yetkin I, Ayvas G et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first-degree relatives of women with polycystic ovary syndrome. Human Reproduction. 2005;20(9):2414-20.

Cite this article as: Yashwant AM, Kokwii PR, Taiseen G. Risk of metabolic syndrome in the first degree relatives of women with polycystic ovarian syndrome. Int J Community Med Public Health 2015;2:441-8.